Cargando…
Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy
AIMS: We aim to provide real-world evidence on the use of ocrelizumab for treating multiple sclerosis (MS), with specific regard to prescription pattern, adherence, persistence, healthcare resource utilization and related costs, also in relation to other disease-modifying treatments (DMTs). METHODS:...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618479/ https://www.ncbi.nlm.nih.gov/pubmed/35953597 http://dx.doi.org/10.1007/s00415-022-11320-7 |
_version_ | 1784821059256582144 |
---|---|
author | Moccia, Marcello Affinito, Giuseppina Berera, Giulia Marrazzo, Giuseppina Piscitelli, Raffaele Carotenuto, Antonio Petracca, Maria Lanzillo, Roberta Triassi, Maria Brescia Morra, Vincenzo Palladino, Raffaele |
author_facet | Moccia, Marcello Affinito, Giuseppina Berera, Giulia Marrazzo, Giuseppina Piscitelli, Raffaele Carotenuto, Antonio Petracca, Maria Lanzillo, Roberta Triassi, Maria Brescia Morra, Vincenzo Palladino, Raffaele |
author_sort | Moccia, Marcello |
collection | PubMed |
description | AIMS: We aim to provide real-world evidence on the use of ocrelizumab for treating multiple sclerosis (MS), with specific regard to prescription pattern, adherence, persistence, healthcare resource utilization and related costs, also in relation to other disease-modifying treatments (DMTs). METHODS: We included 2495 people with MS from the Campania Region (South Italy) who received first or switch DMT prescription from Jan 2018 to Dec 2020, and with at least 6-month follow-up. We collected hospital discharge records, drug prescriptions, and related costs, and calculated persistence (time from first prescription to discontinuation or switch to other DMT), adherence (proportion of days covered (PDC)), annualized hospitalization rate (AHR) for MS-related hospital admissions, and DMT costs. RESULTS: Ocrelizumab was the most commonly prescribed DMT (n = 399; age = 45.74 ± 10.98 years; females = 224), after dimethyl fumarate (n = 588) and fingolimod (n = 401); 26% patients treated with ocrelizumab were naïve. When compared with ocrelizumab, the risk of discontinuation was higher for other highly active DMTs (HR = 3.78; p = 0.01), and low/medium efficacy DMTs (HR = 7.59; p < 0.01). When compared with ocrelizumab, PDC was similar to other highly active DMTs (Coeff = 0.01; p = 0.31), but higher for low/medium efficacy DMTs (Coeff = 0.09; p < 0.01). When compared with ocrelizumab, AHR was similar to other highly active DMTs (Coeff = 0.01; p = 0.51), and low/medium efficacy DMTs (Coeff = 0.01; p = 0.55). When compared with ocrelizumab, DMT monthly costs were higher for other highly active DMTs (Coeff = 92.30; p < 0.01), but lower for low/medium efficacy DMTs (Coeff = − 1043.61; p < 0.01). DISCUSSION: Ocrelizumab was among the most frequently prescribed DMTs, with 26% prescriptions to treatment-naïve patients, suggesting its relevance in addressing unmet clinical needs (e.g., first approved treatment for primary progressive MS). Ocrelizumab was associated with the highest persistence, confirming its favorable benefit-risk profile. Costs for ocrelizumab were lower than those associated to similarly effective DMTs, in absence of changes in healthcare resource utilization. |
format | Online Article Text |
id | pubmed-9618479 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-96184792022-11-01 Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy Moccia, Marcello Affinito, Giuseppina Berera, Giulia Marrazzo, Giuseppina Piscitelli, Raffaele Carotenuto, Antonio Petracca, Maria Lanzillo, Roberta Triassi, Maria Brescia Morra, Vincenzo Palladino, Raffaele J Neurol Original Communication AIMS: We aim to provide real-world evidence on the use of ocrelizumab for treating multiple sclerosis (MS), with specific regard to prescription pattern, adherence, persistence, healthcare resource utilization and related costs, also in relation to other disease-modifying treatments (DMTs). METHODS: We included 2495 people with MS from the Campania Region (South Italy) who received first or switch DMT prescription from Jan 2018 to Dec 2020, and with at least 6-month follow-up. We collected hospital discharge records, drug prescriptions, and related costs, and calculated persistence (time from first prescription to discontinuation or switch to other DMT), adherence (proportion of days covered (PDC)), annualized hospitalization rate (AHR) for MS-related hospital admissions, and DMT costs. RESULTS: Ocrelizumab was the most commonly prescribed DMT (n = 399; age = 45.74 ± 10.98 years; females = 224), after dimethyl fumarate (n = 588) and fingolimod (n = 401); 26% patients treated with ocrelizumab were naïve. When compared with ocrelizumab, the risk of discontinuation was higher for other highly active DMTs (HR = 3.78; p = 0.01), and low/medium efficacy DMTs (HR = 7.59; p < 0.01). When compared with ocrelizumab, PDC was similar to other highly active DMTs (Coeff = 0.01; p = 0.31), but higher for low/medium efficacy DMTs (Coeff = 0.09; p < 0.01). When compared with ocrelizumab, AHR was similar to other highly active DMTs (Coeff = 0.01; p = 0.51), and low/medium efficacy DMTs (Coeff = 0.01; p = 0.55). When compared with ocrelizumab, DMT monthly costs were higher for other highly active DMTs (Coeff = 92.30; p < 0.01), but lower for low/medium efficacy DMTs (Coeff = − 1043.61; p < 0.01). DISCUSSION: Ocrelizumab was among the most frequently prescribed DMTs, with 26% prescriptions to treatment-naïve patients, suggesting its relevance in addressing unmet clinical needs (e.g., first approved treatment for primary progressive MS). Ocrelizumab was associated with the highest persistence, confirming its favorable benefit-risk profile. Costs for ocrelizumab were lower than those associated to similarly effective DMTs, in absence of changes in healthcare resource utilization. Springer Berlin Heidelberg 2022-08-11 2022 /pmc/articles/PMC9618479/ /pubmed/35953597 http://dx.doi.org/10.1007/s00415-022-11320-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Communication Moccia, Marcello Affinito, Giuseppina Berera, Giulia Marrazzo, Giuseppina Piscitelli, Raffaele Carotenuto, Antonio Petracca, Maria Lanzillo, Roberta Triassi, Maria Brescia Morra, Vincenzo Palladino, Raffaele Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy |
title | Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy |
title_full | Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy |
title_fullStr | Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy |
title_full_unstemmed | Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy |
title_short | Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy |
title_sort | persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the campania region of italy |
topic | Original Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618479/ https://www.ncbi.nlm.nih.gov/pubmed/35953597 http://dx.doi.org/10.1007/s00415-022-11320-7 |
work_keys_str_mv | AT mocciamarcello persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly AT affinitogiuseppina persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly AT bereragiulia persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly AT marrazzogiuseppina persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly AT piscitelliraffaele persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly AT carotenutoantonio persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly AT petraccamaria persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly AT lanzilloroberta persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly AT triassimaria persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly AT bresciamorravincenzo persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly AT palladinoraffaele persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly |